Λεξικό .. Allergoid depot immunotherapy

Allergoid depot immunotherapy

Depot allergoid of house dust mite (Dermatophagoides pteronyssinus - D.pt) has been created in line with the principles and methodology established in the successful development of pollen allergoids. Specific immunotherapy with a mite depot allergoid induced significant clinical improvements versus placebo. Safety was assessed as excellent, and no systemic adverse reactions occurred[1].

The allergoid sublingual SIT has been very appreciated by both patients and physicians for the good effectiveness and the high degree of safety guaranteed, in addition to its simplicity of use[2].

Depot allergoids may be used in cluster-SIT, 2 - 3 injections per day of treatment are given once a week during t aduction treatment[3].

References

1. Dokic D, Schnitker J, Narkus A, Cromwell O, Frank E. Clinical effects of specific immunotherapy: a two-year double-blind, placebo-controlled study with a one year follow-up. Prilozi. 2005 Dec;26(2):113-29.

2. Arena A, Barbatano E, Gammeri E, Bruno M, Riva G. Specific immunotherapy [correction of immunotheraphy] of allergic diseases: a three years perspective observational study. Int J Immunopathol Pharmacol. 2003 Sep-Dec;16(3):277-82.

3. Hansen I, Hörmann K, Stuck BA, Schneider-Gêne S, Mösges R, Klimek L. Cluster-immunotherapy in seasonal allergic rhinitis: safety aspects of induction therapy with depot allergoids (Purethal). Laryngorhinootologie. 2003 Aug;82(8):558-63